Tim’s career in the life sciences has encompassed start ups, venture capital, investment banking and equity research. He has held senior positions at a number of firms including NM Rothschild, Hambrecht and Quist, UBS, SG Cowen and Pacific Growth Equities. In 2013 he founded Longcross Advisers, a life science-focused corporate finance firm. He gained his PhD from the MRC’s Laboratory of Molecular Biology in Cambridge and a BSc (Hons) in biochemistry from Imperial College, London.
Kevin began his career in the biotechnology industry at Cambridge Antibody Technology (now part of Medimmune, an AstraZeneca company) when CAT was still in its start-up phase. He went on to found and manage Isogenica Ltd and has since held CEO positions with PhosImmune Inc., Activiomics Ltd and F-star GmbH. Kevin studied for his PhD in the laboratory of Sir Gregory Winter at the MRC Laboratory of Molecular Biology, Cambridge and for his MBA at Aston Business School following receipt of a Sainsbury Management Fellowship from the Royal Academy of Engineering, London.
Ian is an experienced finance executive with 20 years’ experience in pharmaceutical and medical technology companies. He was CFO of Diurnal Group, where he managed the company’s IPO and admission to the AIM Market; Lombard Medical, where he was responsible for the company’s final AIM fundraising followed by its AIM delisting and IPO on NASDAQ; and Biocompatibles International, where he led the group financially to profitability and subsequent sale to BTG. Ian’s experience includes IPOs, fundraising, acquisitions and disposals in private and public Life Sciences companies along with supporting early stage companies with their financial and accounting needs. He is a qualified Chartered Accountant.
Shaun began his industrial career managing development teams and projects for Pfizer and GSK. He moved into the biotech sector in 2006, managing portfolios and product development for Syntaxin and ImmBio. Shaun went on to manage oncology R&D for Biosceptre and Inflection Biosciences as CSO. After obtaining a D.Phil. in cancer cell signalling, he undertook post-doctoral studies at the University of Cambridge researching receptor-mediated signalling and transcriptional regulation. He is a member of the American Society of Clinical Oncology and the American Association for Cancer Research.
Vivienne’s career in the biotech industry includes research management roles at Wellcome Biotech and SmithKline Beecham. She was co-founder of Adprotech Ltd, a company developing novel proteins therapeutics and vaccines. In 2001 she founded UK Bioscience Consultants and has provided life science commercialization consultancy to many of the UK’s leading universities and medical institutes. She holds a PhD from Imperial College, London.